802 related articles for article (PubMed ID: 26899759)
1. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
3. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
Ou SI; Govindan R; Eaton KD; Otterson GA; Gutierrez ME; Mita AC; Argiris A; Brega NM; Usari T; Tan W; Ho SN; Robert F
J Thorac Oncol; 2017 Jan; 12(1):145-151. PubMed ID: 27697581
[TBL] [Abstract][Full Text] [Related]
4. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Park K; Cho BC; Kim DW; Ahn MJ; Lee SY; Gernhardt D; Taylor I; Campbell AK; Zhang H; Giri N; Letrent SP; O'Connell J; Heo DS
J Thorac Oncol; 2014 Oct; 9(10):1523-31. PubMed ID: 25521398
[TBL] [Abstract][Full Text] [Related]
7. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM; Shepherd FA; Millward M; Perrone F; Seymour L; Liu G; Sun S; Cho BC; Morabito A; Leighl NB; Stockler MR; Lee CW; Wierzbicki R; Cohen V; Blais N; Sangha RS; Favaretto AG; Kang JH; Tsao MS; Wilson CF; Goldberg Z; Ding K; Goss GD; Bradbury PA; ; ;
Lancet Oncol; 2014 Nov; 15(12):1379-88. PubMed ID: 25439692
[TBL] [Abstract][Full Text] [Related]
9. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
Yoo SB; Kim YJ; Kim H; Jin Y; Sun PL; Jheon S; Lee JS; Chung JH
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S545-52. PubMed ID: 23579873
[TBL] [Abstract][Full Text] [Related]
10. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Seto T; Kiura K; Nishio M; Nakagawa K; Maemondo M; Inoue A; Hida T; Yamamoto N; Yoshioka H; Harada M; Ohe Y; Nogami N; Takeuchi K; Shimada T; Tanaka T; Tamura T
Lancet Oncol; 2013 Jun; 14(7):590-8. PubMed ID: 23639470
[TBL] [Abstract][Full Text] [Related]
11. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
[TBL] [Abstract][Full Text] [Related]
12. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
[TBL] [Abstract][Full Text] [Related]
14. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
16. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
Ma Y; Zheng X; Zhao H; Fang W; Zhang Y; Ge J; Wang L; Wang W; Jiang J; Chuai S; Zhang Z; Xu W; Xu X; Hu P; Zhang L
J Thorac Oncol; 2018 Jul; 13(7):968-977. PubMed ID: 29626621
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
20. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
